Results 31 to 40 of about 78,685 (264)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma [PDF]

Current Treatment Options in Oncology, 2022
Opinion statementThe therapeutic armamentarium has significantly expanded since the approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in non-Hodgkin lymphoma (NHL). These CAR-Ts are patient-specific and require a complex, resource, and time-consuming process.
Arushi Khurana, Yi Lin
openaire   +2 more sources

Chimeric antigen receptor T cell

Indian Journal of Pharmacology, 2022
During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2/neu inhibitor, has been developed and accepted widely for management of chronic myeloid leukaemia and breast cancer ...
Singh, Surjit, Khasbage, Sameer, Kaur, Rimple Jeet, Sidhu, Jaspreet Kaur, Bhandari, Bharti   +4 more
openaire   +2 more sources

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Nature Communications, 2022
Antigen escape represents a potential drawback of chimeric antigen receptor T cell (CAR-T) therapy targeting a single tumor-associated antigen. To reduce the risk of antigen escape, here the authors report the design and characterization of a BAFF ligand
Derek P. Wong, Nand K. Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey-Son, Samantha Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Paolo Caimi, Reshmi Parameswaran   +12 more
doaj   +1 more source

Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation

Haematologica, 2020
Allogeneic hematopoietic stem cell transplantation is an effective therapy for high-risk leukemias. In children, graft manipulation based on the selective removal of αβ T cells and B cells has been shown to reduce the risk of acute and chronic graft ...
Volker Wiebking, Ciaran M. Lee, Nathalie Mostrel, Premanjali Lahiri, Rasmus Bak, Gang Bao, Maria Grazia Roncarolo, Alice Bertaina, Matthew H. Porteus   +8 more
doaj   +1 more source

The pharmacology of second-generation chimeric antigen receptors [PDF]

Nature Reviews Drug Discovery, 2015
Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to augment their antitumour efficacy. The combined activating and co-stimulatory domains incorporated in these CARs critically determine the function, differentiation, metabolism and persistence of engineered T cells.
Sjoukje J C, van der Stegen, Mohamad, Hamieh, Michel, Sadelain   +2 more
openaire   +2 more sources

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

Nature Communications, 2020
Chimeric antigen receptors (CAR) use antibody variable regions to activate anti-tumor immunity. Here the authors show that a mouse IgH/IgL variable region used in a clinical CAR induces host immune responses to possibly reduce therapy efficacy, but an ...
Norris Lam, Nathan D. Trinklein, Benjamin Buelow, George H. Patterson, Namrata Ojha, James N. Kochenderfer   +5 more
doaj   +1 more source

CAR-T Cells: Precision Cancer Immunotherapy

Indonesian Biomedical Journal, 2018
BACKGROUND: Current cancer drugs and treatments are aiming at eradicating tumor cells, but often are more toxic then effective, killing also the normal cells and not selectively the tumor cells.
Anna Meiliana, Nurrani Mustika Dewi, Andi Wijaya   +2 more
doaj   +1 more source

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.

PLoS ONE, 2015
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although mainly second generation (2G) CARs carrying CD28 or 4-1BB have been investigated in patients, preclinical studies suggest that third generation (3G) CARs
Hannah Karlsson, Emma Svensson, Camilla Gigg, Malin Jarvius, Ulla Olsson-Strömberg, Barbara Savoldo, Gianpietro Dotti, Angelica Loskog   +7 more
doaj   +1 more source

Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens

Nature Communications, 2021
Chimeric antigen receptor T cells in the clinic currently target cell-type-specific extracellular antigens on malignant cells. Here, authors engineer tumor-specific chimeric antigen receptor T cells that target human leukocyte antigen-presented ...
Michael S. Hwang, Michelle S. Miller, Puchong Thirawatananond, Jacqueline Douglass, Katharine M. Wright, Emily Han-Chung Hsiue, Brian J. Mog, Tihitina Y. Aytenfisu, Michael B. Murphy, P. Aitana Azurmendi, Andrew D. Skora, Alexander H. Pearlman, Suman Paul, Sarah R. DiNapoli, Maximilian F. Konig, Chetan Bettegowda, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou, Sandra B. Gabelli   +21 more
doaj   +1 more source

Driving CARs to BARs: The Winding Road to Specific Regulatory T Cells for Tolerance

Frontiers in Immunology, 2021
Chimeric antigen receptor (CAR) transduced T cells have significantly improved cancer immunotherapy. Similarly, engineering regulatory T cells (Treg) with specific receptors to endow specificity and increase efficacy of Tregs holds great promise for ...
David W. Scott
doaj   +1 more source